Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giuliana Guggino, Vasiliki Liakouli, Alessia Alunno, Serena Vettori, Alessandra Bortoluzzi, Francesco Caso, Francesco Ursini, Monica Todoerti, Roberto Caporali, Ricard Cervera, Pierluigi Meroni, Elena Bartoloni-Bocci, Yehuda Shoenfeld, Emmanuel Coloma, Piero Ruscitti, Michele Gilio, Onorina Berardicurti, Roberto Caporali, Maria Gerosa, Salvatore Di BartolomeoPierluigi Meroni, Athanasios G. Tzioufas, Andrea Doria, Guido Valesini, Chiara Rebuffi, Gianluca Moroncini, Salvatore D'Angelo, Michele Bombardieri, Domenico Paolo Emanuele Margiotta, Marcella Prete, Eugen Feist, Maria Sole Chimenti, Federico Perosa, Oliver Distler, Roberta Priori, Salvatore D'Angelo, Guido Valesini, Roberto Giacomelli, Claudio Vitali, Antonella Afeltra, Paola Cipriani, Athanasios G. Tzioufas, Salvatore De Vita, Raffaele Scarpa, Fabrizio Conti, Benjamin A. Fisher

Risultato della ricerca: Articlepeer review

48 Citazioni (Scopus)


Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.
Lingua originaleEnglish
pagine (da-a)93-106
Numero di pagine14
RivistaAutoimmunity Reviews
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2723???
  • ???subjectarea.asjc.2400.2403???


Entra nei temi di ricerca di 'Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis'. Insieme formano una fingerprint unica.

Cita questo